Drug pipeline
Explore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Hepatitis A virus-specific B-cell receptors (HAV-specific BCRs) are membrane-bound immunoglobulins expressed on the surface of HAV-specific B lymphocytes. These receptors play a pivotal role in the adaptive immune response by recognizing and binding to specific antigenic epitopes on the capsid of the Hepatitis A virus (HAV). Upon antigen binding, HAV-specific BCRs undergo cross-linking, which initiates intracellular signaling cascades (such as the phosphorylation of CD79a/b and recruitment of Syk kinase) leading to B-cell activation, proliferation, and differentiation into memory B cells and plasma cells that secrete high-affinity neutralizing anti-HAV antibodies. In clinical practice, these receptors are the primary target of inactivated Hepatitis A vaccines (such as Havrix and Vaqta), which mimic natural infection to stimulate the production of protective IgG antibodies. A notable therapeutic challenge associated with these receptors is the potential inhibition of vaccine-induced B-cell activation in infants by maternal antibodies, which can cross-link the BCR with the inhibitory FcγRIIB receptor.
Binding of vaccine antigens (inactivated Hepatitis A virus) to the B-cell receptor, inducing receptor cross-linking, intracellular signaling, B-cell activation, clonal expansion, and differentiation into neutralizing antibody-secreting plasma cells and memory B cells.
5 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Hepatitis A virus-specific B-cell receptor (HAV-specific BCR).